Severe Atopic Dermatitis
Greater atopic dermatitis severity linked to worse quality of life in pediatric patients
Pediatric patients with severe atopic dermatitis experienced higher rates of itch, pain, sleep disturbances and missed school days compared with those with mild disease, according to a study.
Rademikibart maintains efficacy in atopic dermatitis through 1 year
Long-term trial results showed efficacy of rademikibart in Chinese patients with moderate to severe atopic dermatitis, Connect Biopharma announced in a press release.
European Commission approves Ebglyss for adults, adolescents with atopic dermatitis
The European Commission has approved Ebglyss in the European Union for the treatment of moderate to severe atopic dermatitis in adults and adolescents aged 12 years and older, Almirall announced in a press release.
Lebrikizumab maintenance dosing achieves dermatitis clearance up to 2 years
Maintenance dosing of lebrikizumab sustained skin clearance, relieved itch and reduced disease severity for up to 2 years in patients with moderate to severe atopic dermatitis, Eli Lilly and Company announced in a press release.
Amlitelimab shows promise as treatment for moderate to severe atopic dermatitis
Amlitelimab exhibited clinically meaningful efficacy over 24 weeks in the treatment of adults with moderate to severe atopic dermatitis, according to study results presented at the European Academy of Dermatology and Venereology 2023 Congress.
At 1 year, tralokinumab efficacious for atopic dermatitis treatment in adolescents
Tralokinumab at doses of 150 mg or 300 mg was associated with improvements over placebo in a number of efficacy outcomes at 16 weeks and 52 weeks in adolescents with moderate to severe atopic dermatitis, according to a study.
Baricitinib ‘potential therapeutic option’ for moderate to severe atopic dermatitis
A 4 mg dose of baricitinib was associated with significant improvement over placebo in a number of efficacy parameters in patients with moderate to severe atopic dermatitis, according to a study.
Dupixent approved in EU for infants, young children with severe atopic dermatitis
The European Commission approved Dupixent in the European Union for the treatment of severe atopic dermatitis in infants and young children who are candidates for systemic therapy, Sanofi and Regeneron announced in a press release.
New drug effective, safe in long-term treatment of moderate to severe atopic dermatitis
Patients with moderate to severe atopic dermatitis showed promising results during and up to 20 weeks after treatment in a clinical trial evaluating rocatinlimab, according to a study.
Safety data show Adbry well tolerated in treatment of moderate to severe atopic dermatitis
The results of pooled safety data for Adbry showed positive effects in the prolonged treatment of moderate to severe atopic dermatitis, according to a study.